Search Medical Condition
Bladder Carcinoma Clinical Trials
A listing of Bladder Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (279) clinical trials
A Phase 3 Study (PHOCUS) to determine whether the oncolytic virus immunotherapy called Pexa-Vec (JX-594) can slow the progression of advanced liver cancer (hepatocellular carcinoma or HCC).
This research study is for people with advanced liver cancer who have never received systemic medicine (affecting the entire body) for advanced liver cancer. This is a randomized, open-label Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib can slow the progression of ...
Study title: A randomized, double blind, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment. Approximately 560 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to regorafenib or placebo (1/3 chance to receive placebo). Primary endpoint of ...
A Phase III randomized, placebo-controlled, double-blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)
This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially ...
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG. Clinical trial NCT02449239, VB4-845-02-IIIA.
Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. Vicinium is an experimental agent that may provide an alternative to cystectomy.
Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor
- This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme ...
Blood Sample – Diagnosed With or At Risk for Hepatocellular Carcinoma
A research study is collecting blood samples to better understand biomarkers in adults recently diagnosed with or at risk for developing Hepatocellular Carcinoma (HCC). Those with hepatitis B or C, nonalcoholic steatohepatitis (NASH), cirrhosis or other forms of liver disease may be at risk.
Fierce-21: A Phase 1/2(b) Study of Vofatamab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
The FIERCE-21 study is a Phase 1/2(b) study to evaluate the effectiveness and safety of Vofatamab alone (monotherapy) and vofatamab plus docetaxel versus placebo plus docetaxel in the treatment of subjects with Stage IV, locally advanced or metastatic FGFR mutation positive UCC who have previously been treated for their bladder ...
Fierce-22: A Phase 1b/2 Study of Vofatamab (B-701) in Combination with Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
The FIERCE-22 study is a Phase 1b/2 study to evaluate the effectiveness and safety of vofatamab (B-701) in combination with the immunotherapy drug pembrolizumab in the treatment of subjects with Stage IV, locally advanced or metastatic FGFR3 wild-type (WT) or mutation positive UCC who have previously been treated with a ...
A Humanitarian Use Device trial for patients who have hepatocellular carcinoma of the liver.
A Humanitarian Use Device trial for patients who have hepatocellular carcinoma of the liver.
